Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of “Buy” from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has earned an average rating of “Buy” from the ten brokerages that are currently covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $40.38.

Several research firms have commented on ORKA. BTIG Research began coverage on shares of Oruka Therapeutics in a research report on Thursday, May 22nd. They set a “buy” rating on the stock. HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research report on Friday, February 7th. Wall Street Zen raised shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Wolfe Research initiated coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price target for the company. Finally, Wedbush restated an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Thursday, May 15th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ORKA. China Universal Asset Management Co. Ltd. purchased a new position in Oruka Therapeutics in the 4th quarter valued at approximately $144,000. AlphaCentric Advisors LLC purchased a new position in Oruka Therapeutics in the 4th quarter valued at approximately $119,000. Charles Schwab Investment Management Inc. purchased a new position in Oruka Therapeutics in the 4th quarter valued at approximately $303,000. Vanguard Group Inc. grew its stake in Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock valued at $31,231,000 after buying an additional 1,572,853 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in Oruka Therapeutics in the 4th quarter valued at approximately $54,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics Stock Down 6.8%

Oruka Therapeutics stock opened at $11.04 on Monday. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $31.13. The company’s 50 day moving average price is $9.73 and its two-hundred day moving average price is $13.61. The stock has a market cap of $413.35 million, a P/E ratio of -1.76 and a beta of 0.25.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. On average, equities analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.